{"entity":{"id":"gilles-salles","kind":"person","name":"Gilles Salles","aka":[],"tldr":"Led PRIMA, which established rituximab maintenance in follicular lymphoma, and co-chaired POLARIX in DLBCL.","summary":"Gilles Salles led PRIMA, the trial showing two years of rituximab maintenance prolongs remission in follicular lymphoma, and co-chaired POLARIX, which showed polatuzumab vedotin plus R-CHP improves progression-free survival over R-CHOP in DLBCL, the first new first-line regimen in two decades. He led the French LYSA group before moving to MSKCC and co-led the tafasitamab and mosunetuzumab programmes.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Gilles_Salles","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Salles%20G%5BAuthor%5D%20lymphoma"}],"tags":["lymphoma","trialist","lysa"],"related":[],"cancers":["follicular-lymphoma","dlbcl"],"sections":[],"technologies":["monoclonal-antibody","adc"],"targets":["cd20"],"drugs":[],"companies":["lysa"],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":["polarix"],"people":[],"bottlenecks":[],"keyPapers":["paper-polarix-polatuzumab-rchp-nejm-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Follicular lymphoma","Diffuse large B-cell lymphoma","Anti-CD20 antibodies","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Salles%20G%5BAuthor%5D%20lymphoma"}],"papers":[{"title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA)","journal":"Lancet","year":2011,"doi":"10.1016/S0140-6736(10)62175-7"},{"title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma (POLARIX)","journal":"NEJM","year":2022,"doi":"10.1056/NEJMoa2115304"}],"orcid":"0000-0002-9541-8666"},"route":"/people/gilles-salles/","neighbours":{"cancer":[{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"follicular-lymphoma","kind":"cancer","name":"Follicular lymphoma","route":"/cancers/follicular-lymphoma/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"company":[{"id":"lysa","kind":"company","name":"LYSA (The Lymphoma Study Association)","route":"/companies/lysa/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"trial":[{"id":"polarix","kind":"trial","name":"POLARIX","route":"/trials/polarix/"},{"id":"prima-follicular","kind":"trial","name":"PRIMA","route":"/trials/prima-follicular/"},{"id":"remarc","kind":"trial","name":"REMARC","route":"/trials/remarc/"}],"paper":[{"id":"paper-zuma-5-axi-cel-indolent-lymphoma-lancet-oncol-2022","kind":"paper","name":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial","route":"/key-papers/paper-zuma-5-axi-cel-indolent-lymphoma-lancet-oncol-2022/"},{"id":"paper-remarc-lenalidomide-maintenance-dlbcl-jco-2017","kind":"paper","name":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line R-CHOP","route":"/key-papers/paper-remarc-lenalidomide-maintenance-dlbcl-jco-2017/"},{"id":"paper-polarix-polatuzumab-rchp-nejm-2022","kind":"paper","name":"POLARIX: swapping vincristine for the antibody-drug conjugate polatuzumab vedotin in first-line treatment of diffuse large B-cell lymphoma","route":"/key-papers/paper-polarix-polatuzumab-rchp-nejm-2022/"},{"id":"paper-prima-rituximab-maintenance-follicular-lancet-2011","kind":"paper","name":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","route":"/key-papers/paper-prima-rituximab-maintenance-follicular-lancet-2011/"},{"id":"paper-prima-final-rituximab-maintenance-follicular-jco-2019","kind":"paper","name":"Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study","route":"/key-papers/paper-prima-final-rituximab-maintenance-follicular-jco-2019/"}],"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}]}}